BBT-176 is a first-in-class fourth-generation EGFR TKI designed to inhibit EGFRC797S mutation that arises following osimertinib treatment in patients with NSCLC and is in a phase 1–2 clinical trial for advanced NSCLC [82]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.